Autonomic Dysfunction
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Martin PharmaceuticalsNY - New York
1 programAutonomic Dysfunction and Inflammation in Chronic Hemodialysis PatientsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Overland TherapeuticsDevelopment of AD/OI after BS
Martin PharmaceuticalsAutonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients
Clinical Trials (2)
Total enrollment: 445 patients across 2 trials
Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study
Start: Feb 2024Est. completion: Dec 2025400 patients
N/ARecruiting
NCT00878033Martin PharmaceuticalsAutonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients
Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients
Start: Apr 2009Est. completion: Dec 201045 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 445 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.